GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000915212 | Liver | HCC | purine ribonucleotide biosynthetic process | 101/7958 | 169/18723 | 4.30e-06 | 5.50e-05 | 101 |
GO:000663321 | Liver | HCC | fatty acid biosynthetic process | 96/7958 | 163/18723 | 1.71e-05 | 1.85e-04 | 96 |
GO:007252212 | Liver | HCC | purine-containing compound biosynthetic process | 114/7958 | 200/18723 | 2.36e-05 | 2.49e-04 | 114 |
GO:00973521 | Liver | HCC | autophagosome maturation | 30/7958 | 40/18723 | 3.04e-05 | 3.12e-04 | 30 |
GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
GO:00338661 | Liver | HCC | nucleoside bisphosphate biosynthetic process | 41/7958 | 60/18723 | 4.65e-05 | 4.49e-04 | 41 |
GO:00340301 | Liver | HCC | ribonucleoside bisphosphate biosynthetic process | 41/7958 | 60/18723 | 4.65e-05 | 4.49e-04 | 41 |
GO:00340331 | Liver | HCC | purine nucleoside bisphosphate biosynthetic process | 41/7958 | 60/18723 | 4.65e-05 | 4.49e-04 | 41 |
GO:000616412 | Liver | HCC | purine nucleotide biosynthetic process | 107/7958 | 191/18723 | 1.08e-04 | 9.22e-04 | 107 |
GO:00353841 | Liver | HCC | thioester biosynthetic process | 31/7958 | 45/18723 | 3.11e-04 | 2.21e-03 | 31 |
GO:00716161 | Liver | HCC | acyl-CoA biosynthetic process | 31/7958 | 45/18723 | 3.11e-04 | 2.21e-03 | 31 |
GO:00353371 | Liver | HCC | fatty-acyl-CoA metabolic process | 26/7958 | 38/18723 | 1.11e-03 | 6.33e-03 | 26 |
GO:0006665 | Liver | HCC | sphingolipid metabolic process | 85/7958 | 155/18723 | 1.27e-03 | 6.92e-03 | 85 |
GO:1901568 | Liver | HCC | fatty acid derivative metabolic process | 43/7958 | 74/18723 | 4.85e-03 | 2.04e-02 | 43 |
GO:0046949 | Liver | HCC | fatty-acyl-CoA biosynthetic process | 17/7958 | 25/18723 | 8.94e-03 | 3.45e-02 | 17 |
GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
GO:001969319 | Oral cavity | OSCC | ribose phosphate metabolic process | 199/7305 | 396/18723 | 2.97e-06 | 3.64e-05 | 199 |
GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
GO:000925919 | Oral cavity | OSCC | ribonucleotide metabolic process | 189/7305 | 385/18723 | 3.18e-05 | 2.87e-04 | 189 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TEC | SNV | Missense_Mutation | | c.1117A>T | p.Met373Leu | p.M373L | P42680 | protein_coding | tolerated(1) | benign(0.037) | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEC | SNV | Missense_Mutation | rs780984861 | c.1393N>A | p.Val465Ile | p.V465I | P42680 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-AO-A12A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TEC | SNV | Missense_Mutation | | c.1564T>G | p.Ser522Ala | p.S522A | P42680 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
TEC | SNV | Missense_Mutation | | c.1191C>G | p.Ile397Met | p.I397M | P42680 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEC | SNV | Missense_Mutation | | c.700N>T | p.Val234Leu | p.V234L | P42680 | protein_coding | tolerated(0.4) | probably_damaging(0.997) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
TEC | SNV | Missense_Mutation | rs761984494 | c.806N>A | p.Gly269Asp | p.G269D | P42680 | protein_coding | deleterious(0) | benign(0.403) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
TEC | insertion | In_Frame_Ins | novel | c.587_588insAAATATAAAATTTAATTTCCCTCAAGGTCAAAATAATCACATTAAACA | p.Gly195_His196insGlnAsnIleLysPheAsnPheProGlnGlyGlnAsnAsnHisIleLys | p.G195_H196insQNIKFNFPQGQNNHIK | P42680 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TEC | deletion | Frame_Shift_Del | novel | c.1348delN | p.Leu450PhefsTer2 | p.L450Ffs*2 | P42680 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TEC | SNV | Missense_Mutation | rs750190240 | c.700N>A | p.Val234Ile | p.V234I | P42680 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TEC | SNV | Missense_Mutation | rs539573453 | c.550N>A | p.Val184Ile | p.V184I | P42680 | protein_coding | deleterious(0.05) | benign(0.039) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |